Biothera Pharmaceuticals to Present at the Sachs Associates 2nd Annual Immuno-Oncology: BD&L and Investment Forum

EAGAN, Minn.--()--Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Sachs Associates 2nd Annual Immuno-Oncology: BD&L and Investment Forum on Friday, June 3, 2016 at 2:30 p.m. Central Time in Chicago.

Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology, which include the initiation of three Phase 2 studies this year to evaluate the combination of company’s developmental immunotherapeutic and checkpoint inhibitors in NSCLC, metastatic melanoma and gastric cancer.

About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in trials in over 400 subjects and has established proof of concept in multiple clinical studies, including single-arm and randomized phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer, and chronic lymphocytic leukemia.

Contacts

Biothera Pharmaceuticals, Inc.
David Walsh, 651-256-4606
SVP Communications
dwalsh@biothera.com

Release Summary

Biothera Pharmaceuticals CEO Barry Labinger will present the company's clinical development plans in oncology at the Sachs Associates Immuno-Oncology: BD&L and Investment Forum on Friday, June 3.

Contacts

Biothera Pharmaceuticals, Inc.
David Walsh, 651-256-4606
SVP Communications
dwalsh@biothera.com